BioRestorative Therapies logo
BioRestorative Therapies
BRTX | NASDAQ
Chart Builder DCF Calculator
$1.37
-$0.12 (-8.05%)
At close: Nov 16, 2026, 3:59 PM ET
$1.39
+$0.02 (+1.46%)
After-hours: Nov 16, 2026, 7:58 PM ET

BioRestorative Therapies Company Profile

Company profile explained

Company Profile

BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.

Key Executives

Name Position
Katharyn Field President, CEO, Interim CFO, Treasurer & Secretary and Director
Mika Grasso Interim CEO & Director
Anna Skowron CFO & Treasurer
Crystal Romano Head of Global Commercial Operations
Francisco J. Silva VP of Research & Development, Secretary & Chief Scientist

Latest SEC Filings

Date Type Title
Oct 09, 2026 8-K Current Report
Sep 11, 2026 8-K Current Report
Sep 10, 2026 8-K/A [Amend] Current Report
Sep 02, 2026 8-K Current Report
Sep 02, 2026 8-K Current Report
Aug 25, 2026 8-K Current Report
Aug 14, 2026 NT 10-Q Filing
Aug 14, 2026 8-K Current Report
Aug 03, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jul 30, 2026 3 Filing
View All SEC Filings ➞
BioRestorative Therapies
BioRestorative Therapies logo
Country United States
IPO Date Dec 5, 2012
Industry Biotechnology
Sector Healthcare
Employees 14
CEO Katharyn Field

Contact Details

40 Marcus Drive Melville, New York 11747 United States

Stock Details

Ticker Symbol BRTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001505497
CUSIP Number 090655705
ISIN Number US0906557055
SIC Code 8090

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.